Equities

Bioventix PLC

BVXP:LSE

Bioventix PLC

Health CarePharmaceuticals and Biotechnology
  • Price (GBX)3,750.00
  • Today's Change40.00 / 1.08%
  • Shares traded3.85k
  • 1 Year change-5.06%
  • Beta0.2825
Data delayed at least 20 minutes, as of Nov 22 2024 16:01 GMT.
More ▼

Profile data is unavailable for this security.

About the company

Bioventix plc is a United Kingdom-based company specializing in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, such as in automated immunoassays used in blood testing. The antibodies created at the Company are generated in sheep and are of particular benefit where the target is present at low concentration and where conventional monoclonal or polyclonal antibodies have failed to produce a suitable reagent. It offers a portfolio of antibodies to customers for both commercial use and research and development purposes, for the diagnosis or monitoring of a broad range of conditions, including heart disease, cancer, fertility, thyroid function, and drug abuse. The Company’s products include sheep monoclonal antibodies (SMAs), Pyrene (HOP-G) ELISA Kits, and Pyrene (HOP-G) Lateral Flow Kits. The Company supplies antibody products and services to the majority of multinational clinical diagnostics companies.

  • Revenue in GBP (TTM)13.61m
  • Net income in GBP8.10m
  • Incorporated2003
  • Employees17.00
  • Location
    Bioventix PLC7 Romans Business Park, East StreetFARNHAM GU9 7SXUnited KingdomGBR
  • Phone+44 12 5272 8001Fax+44 12 5272 8002
  • Websitehttps://www.bioventix.com/
More ▼

Peer analysis

CompanyRevenue (TTM)Net income (TTM)Market capEmployeesMarket Cap /
Employees
Futura Medical PLC8.40m-3.75m100.75m12.00100.75m12.00
Scancell Holdings Plc0.00-5.86m134.79m61.00134.79m61.00
Faron Pharmaceuticals Oy0.00-26.30m148.85m34.00148.85m34.00
hVIVO PLC64.38m17.45m155.81m274.00155.81m274.00
4Basebio PLC596.00k-9.84m166.54m--166.54m--
Avacta Group Plc22.62m-25.89m171.73m154.00171.73m154.00
Bioventix PLC13.61m8.10m193.65m17.00193.65m17.00
Allergy Therapeutics plc55.20m-40.22m247.85m635.00247.85m635.00
Puretech Health PLC371.84k-65.52m389.83m90.00389.83m90.00
Oxford BioMedica plc97.28m-142.02m436.93m834.00436.93m834.00
Data as of Nov 22 2024. Currency figures normalised to Bioventix PLC's reporting currency: UK Pound GBX

Institutional shareholders

61.60%Per cent of shares held by top holders
HolderShares% Held
Liontrust Investment Partners LLPas of 24 Oct 2024574.16k11.00%
Sanford DeLand Asset Management Ltd.as of 24 Oct 2024568.94k10.90%
Link Fund Solutions Ltd.as of 31 May 2024363.63k6.97%
Gresham House Asset Management Ltd. (Investment Management)as of 01 Jun 2024363.00k6.95%
Rathbones Investment Management Ltd.as of 24 Oct 2024323.62k6.20%
Schroder Investment Management Ltd.as of 24 Oct 2024287.08k5.50%
Investec Wealth & Investment Ltd.as of 01 Jun 2024243.00k4.66%
Santander Asset Management UK Ltd.as of 01 Jun 2024207.00k3.97%
Danske Bank A/S (Investment Management)as of 31 Oct 2024185.66k3.56%
Hargreaves Lansdown Asset Management Ltd.as of 01 Jun 202499.00k1.90%
More ▼
Data from 31 May 2024 - 05 Nov 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.